| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1996.14.7.2101 |
| P698 | PubMed publication ID | 8683243 |
| P50 | author | Michael L. Berman | Q97448902 |
| Dominique Belpomme | Q3034980 | ||
| P2093 | author name string | P Rose | |
| G Kemp | |||
| A Manetta | |||
| H Homesley | |||
| J Glick | |||
| B Roullet | |||
| J Lurain | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| amifostine | Q251698 | ||
| P304 | page(s) | 2101-2112 | |
| P577 | publication date | 1996-07-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer | |
| P478 | volume | 14 |
| Q43824283 | A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188). |
| Q46469682 | A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer |
| Q44248905 | A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients |
| Q46403955 | A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. |
| Q74222622 | A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors |
| Q28346786 | A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation |
| Q33330520 | A risk-benefit assessment of amifostine in cytoprotection |
| Q44380836 | Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. |
| Q77381801 | Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate |
| Q31437264 | Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study |
| Q40883862 | Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line |
| Q37480824 | Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group |
| Q33367096 | Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study |
| Q38633284 | Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models. |
| Q31373959 | Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study |
| Q44533914 | Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies |
| Q36825081 | Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma |
| Q73923837 | Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained |
| Q47181301 | Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma |
| Q36866297 | Amifostine reduces lung vascular permeability via suppression of inflammatory signalling |
| Q44221521 | Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. |
| Q34257881 | Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome |
| Q40449852 | Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53. |
| Q44044542 | An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer |
| Q30486848 | Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer |
| Q32060398 | Anticancer drug-induced kidney disorders |
| Q43754204 | Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. |
| Q35019735 | Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group |
| Q30651272 | Bone marrow stem cell protection from chemotherapy by low--molecular-weight compounds |
| Q41438485 | Cancer chemotherapy in older adults. A tolerability perspective |
| Q90403731 | Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review |
| Q33588520 | Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. |
| Q28818565 | Chemotherapy-induced neuropathies-a growing problem for patients and health care providers |
| Q43121191 | Chemotherapy-induced peripheral neuropathy. Part II. Prevention |
| Q35838958 | Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies |
| Q35925635 | Chemotherapy-induced peripheral neurotoxicity |
| Q36057728 | Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics |
| Q39223600 | Cisplatin nephrotoxicity: a review of the literature |
| Q37989844 | Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update |
| Q96135177 | Cisplatin-induced renal toxicity in elderly people |
| Q33585345 | Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer |
| Q33638876 | Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma |
| Q40538938 | Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma |
| Q77522856 | Cumulative toxicities from cisplatin therapy and current cytoprotective measures |
| Q34804920 | Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. |
| Q80510512 | DNA-binding agents |
| Q53154188 | Developing better mouse models to study cisplatin-induced kidney injury. |
| Q77348057 | Differentiation therapy of myelodysplastic syndromes: fact or fiction? |
| Q36924702 | Do antioxidants interfere with radiation therapy for cancer? |
| Q44466715 | Does amifostine have a role in chemoradiation treatment? |
| Q33996151 | Drug therapy for gynaecological cancer in older women |
| Q36125552 | Drug-induced acute kidney injury in children |
| Q36239611 | Drug-induced hypomagnesaemia : scope and management |
| Q33336782 | Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany |
| Q44466271 | Effect of 5-aminosalicylic acid on radiation-induced micronuclei in mouse bone marrow. |
| Q78022255 | Effect of amifostine (Ethyol) on the development of extraembryonic blood vessels in chick embryos |
| Q33738758 | Efficacy and tolerability of amifostine in elderly cancer patients |
| Q33774892 | Efficacy of Drug Interventions for Chemotherapy-Induced Chronic Peripheral Neurotoxicity: A Network Meta-analysis |
| Q74754692 | Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer |
| Q94561331 | Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer |
| Q41648536 | Free radicals and antioxidants in chemotherapy-induced toxicity |
| Q37293994 | Genetic variants associated with cisplatin-induced ototoxicity |
| Q53130182 | Geraniin ameliorates cisplatin-induced nephrotoxicity in mice. |
| Q34071798 | Has the outlook improved for amifostine as a clinical radioprotector? |
| Q77291788 | Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS? |
| Q73453245 | High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma |
| Q55241487 | In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials. |
| Q39710489 | In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue |
| Q40914469 | In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065. |
| Q77827608 | In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients |
| Q92499700 | Interventions for cisplatin-induced hearing loss in children and adolescents with cancer |
| Q24197763 | Interventions for preventing neuropathy caused by cisplatin and related compounds |
| Q24236661 | Interventions for preventing neuropathy caused by cisplatin and related compounds |
| Q24246530 | Interventions for preventing neuropathy caused by cisplatin and related compounds |
| Q44661107 | Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study |
| Q48244563 | Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance |
| Q33788925 | Late toxicity following curative treatment of testicular cancer |
| Q40549941 | Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel–Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group |
| Q41586639 | Long-term survivors of childhood cancer. The medical consequences of cure |
| Q34348052 | Malignancy and renal disease |
| Q91625343 | Mechanisms of Cisplatin-Induced Ototoxicity and Prevention |
| Q64098643 | Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity |
| Q43837277 | Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients |
| Q73238889 | Neurologic Complications of Cancer Therapy |
| Q46605095 | Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologo |
| Q35187357 | Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management |
| Q35692169 | Neurotoxicity caused by the treatment with platinum analogues |
| Q36226275 | New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy |
| Q43991047 | New liquid chromatographic assay with electrochemical detection for the measurement of amifostine and WR1065. |
| Q34925061 | OTOTOXIC EFFECTS OF CARBOPLATIN IN ORGANOTYPIC CULTURES IN CHINCHILLAS AND RATS |
| Q32137542 | PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial |
| Q45274552 | Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group |
| Q38062820 | Paediatric genitourinary cancers and late effects of treatment |
| Q33744706 | Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. |
| Q73875834 | Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer |
| Q74700014 | Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice |
| Q35182963 | Pharmacological factors influencing anticancer drug selection in the elderly |
| Q35579412 | Pharmacology of Anticancer Drugs in the Elderly Population |
| Q73308736 | Pharmacology of antineoplastic agents in older cancer patients |
| Q38637751 | Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy |
| Q36616896 | Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. |
| Q43732876 | Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma |
| Q52905253 | Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. |
| Q33811941 | Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches |
| Q35345734 | Platinum-induced neurotoxicity and preventive strategies: past, present, and future |
| Q49691119 | Podophyllotoxin and rutin in combination prevents oxidative stress mediated cell death and advances revival of mice gastrointestine following lethal radiation injury |
| Q39983001 | Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer |
| Q28486646 | Pre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in mice |
| Q93073304 | Prevalence and Predictors of Cisplatin-Induced Peripheral Neuropathy at the Kenyatta National Hospital |
| Q48106419 | Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms. |
| Q38172382 | Prevention and treatment of chemotherapy-induced peripheral neuropathy |
| Q53760013 | Prevention of cisplatin nephrotoxicity. |
| Q92183813 | Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline |
| Q47716828 | Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss. |
| Q46391449 | Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation |
| Q44600043 | Protective Effect of Amifostine Against Toxicity of Paclitaxel and Carboplatin in Non-small Cell Lung Cancer: A Single Center Randomized Study |
| Q38738226 | Protective effect of amifostine on busulfan induced DNA damage in human hepatoma cells |
| Q34848120 | Radiation enteritis |
| Q46452016 | Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer |
| Q33178760 | Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group |
| Q77291806 | Reducing the toxicity of anticancer therapy: new strategies |
| Q44207268 | Renal toxicity after total body irradiation |
| Q47552411 | Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy |
| Q38718953 | Role of Nigella sativa and Its Constituent Thymoquinone on Chemotherapy-Induced Nephrotoxicity: Evidences from Experimental Animal Studies |
| Q44615989 | Role of poly(ADP-ribose)polymerase in cisplatin-induced injury in LLC-PK1 cells |
| Q43639242 | Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy |
| Q34133677 | Scientists and clinicians test their metal-back to the future with platinum compounds |
| Q33502958 | Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer |
| Q34564943 | Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? |
| Q91844349 | Sperm DNA Damage in Cancer Patients |
| Q44608537 | Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model |
| Q43429878 | Survey of Policies and Guidelines on Antioxidant Use for Cancer Prevention, Treatment, and Survivorship in North American Cancer Centers: What Do Institutions Perceive as Evidence? |
| Q34571696 | Thalidomide in myelodysplastic syndromes |
| Q77809158 | The clinical development of paclitaxel and the paclitaxel/carboplatin combination |
| Q42806263 | The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. |
| Q36135801 | The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance |
| Q44803416 | The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys |
| Q41283934 | The need for cytoprotection |
| Q33958507 | The potential role of amifostine in the treatment of non small cell lung cancer |
| Q33653212 | The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects |
| Q77748079 | Toxicity antagonists in head and neck cancer |
| Q33337664 | Treatment of patients with myelodysplastic syndrome with amifostine |
| Q43747293 | Treatment with cisplatin and etoposide in patients with neuroendocrine tumors |
| Q31812154 | Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation |
| Q28078232 | Vincristine-induced peripheral neuropathy in pediatric cancer patients |
| Q44580650 | WITHDRAWN: Addition of amifostine to CHOP regimen significantly reduced toxicity in patients with aggressive non-Hodgkin's lymphoma without affecting the long term survival: Results of a phase II trial |
| Q30492649 | WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects |
| Q33824948 | [EXPRESS] Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect? |
| Q38293704 | p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. |
Search more.